What is breast‑implant‑associated anaplastic large‑cell lymphoma (BIA‑ALCL)?

What is Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)?

BIA-ALCL is a rare T-cell non-Hodgkin lymphoma that develops around breast implants—particularly textured implants—typically presenting as a late-onset peri-implant fluid collection (seroma) occurring a median of 8 to 10 years after implantation. 1

Disease Classification and Pathology

• BIA-ALCL is a distinct clinical entity recognized by the World Health Organization in 2016 as a CD30-positive, ALK-negative T-cell lymphoma that arises in the fibrous capsule surrounding breast implants. 2, 3

• The malignant cells are large and pleomorphic with irregular nuclei, prominent nucleoli, and abundant basophilic cytoplasm, often displaying characteristic "hallmark cells" with horseshoe- or kidney-shaped nuclei. 4

• By definition, tumor cells are strongly and uniformly CD30-positive and ALK-negative, distinguishing this entity from systemic ALK-positive ALCL. 1

Epidemiology and Risk Factors

• The prevalence is approximately 30.54 cases per 100,000 patients with textured implants (1 in 3,274 implanted patients), though the overall prevalence across all implant types is lower at 6.70 per 100,000 (1 in 14,925). 5

• Textured-surface breast implants are the primary risk factor, with nearly all confirmed cases associated with textured rather than smooth implants due to their propensity to trigger chronic local inflammation and immune stimulation. 6, 3

• The disease develops regardless of whether implants were placed for cosmetic augmentation or post-mastectomy reconstruction, with indications split nearly evenly when data are available. 1

• Patients typically present 8 to 10 years after initial implantation, though cases have been reported as early as 4 to 10 months; many patients have had multiple implant exchanges over time. 1

Clinical Presentation

• The most common presentation is new-onset breast swelling, asymmetry, or sensation of fullness caused by peri-implant effusion (seroma) that develops more than 1 year after implantation. 1, 2

• Less commonly, patients present with a palpable mass adjacent to the implant, which should be evaluated with ultrasound, CT, MRI, or PET imaging. 1

• Effusions may be mistaken for implant rupture or capsular contracture (scar tissue buildup), leading to delayed or missed diagnosis. 1

• Additional presentations include overlying skin rashes, lymphadenopathy, capsular contracture, and rarely B-type symptoms, though most disease is localized at diagnosis. 7, 8

Diagnostic Approach

Initial Evaluation

• When peri-implant effusion is present, ultrasound-guided fine-needle aspiration (FNA) of at least 10 to 50 mL of fluid is the essential first diagnostic step, providing material for cytology, immunohistochemistry, flow cytometry, and molecular studies. 1

• Percutaneous aspiration is diagnostic only and not therapeutic; note that small volumes of peri-implant fluid may be normal and incidental. 1

Specimen Processing

• Fresh effusion fluid should be processed immediately via cytocentrifugation to produce air-dried smears stained with Wright-Giemsa or Romanowsky-type stains, which preserve morphologic detail of hematolymphoid cells. 1, 4

• Cell-block preparation is mandatory for H&E histology, immunohistochemistry (CD30, ALK, T-cell markers), and PCR-based T-cell receptor gene rearrangement studies. 4

• Flow cytometry (if a validated CD30 antibody is available) serves as a second-line test, typically showing CD45+, CD30+, CD3-negative or dim cells with aberrant T-cell antigen expression. 4

Immunophenotype

• CD30 is strongly and uniformly positive (membranous pattern) by definition. 1

• ALK-1 is negative, excluding systemic ALK-positive ALCL. 1

• Pan-T-cell markers (CD2, CD3, CD5, CD7) often show aberrant or incomplete expression, while CD4 and CD43 are more commonly preserved. 1

• Cytotoxic proteins (TIA-1, granzyme B, perforin) are frequently positive. 1

• Additional markers exclude mimics: CD20/PAX5 rule out B-cell lymphomas, pan-cytokeratin excludes carcinoma, and EBV-EBER in-situ hybridization excludes EBV-associated lymphomas. 1, 4

Molecular Studies

• T-cell receptor (TCR) gene rearrangement PCR (BIOMED-2 primers) detects clonal rearrangements, supporting a neoplastic T-cell process. 4

Prognosis and Clinical Behavior

• BIA-ALCL has a relatively indolent clinical course with excellent prognosis when disease is confined to the capsule (early stage), as most patients present with localized disease. 3, 7

• Complete surgical excision (capsulectomy with implant removal) is curative for T1-T3 stage disease, unlike other T-cell lymphomas where surgery plays a minimal role. 2, 7

• Infiltrative disease with lymph node involvement or palpable mass carries a worse prognosis, with disease-related mortality up to 40% within 2 years in advanced cases. 7

• As of July 2019, the FDA had cited 573 global medical device reports of BIA-ALCL, including 33 deaths, underscoring that while rare, the disease can be fatal if advanced or disseminated. 2

Staging and Multidisciplinary Management

• Confirmed diagnoses require lymphoma oncology consultation, multidisciplinary evaluation, and PET-CT or CT imaging prior to surgical treatment. 8

• Capsular mapping at capsulectomy with systematic examination of the fibrous capsule determines microscopic tumor involvement and depth of invasion (T-stage 1–4). 4

• For advanced or disseminated disease, treatment follows standard T-cell lymphoma protocols including chemotherapy, though surgical excision remains a key component when feasible. 3, 8

Common Pitfalls

• BIA-ALCL may be missed if peri-implant effusion fluid is not processed promptly or if the capsulectomy specimen is inadequately sampled, leading to false-negative results. 4

• Serial drainages prior to definitive aspiration may artificially lower tumor burden, making diagnosis difficult; larger volume samples or centrifugation concentration may be necessary. 1

• Reactive activated T cells may express CD30, so correlation with morphology, light-scatter properties on flow cytometry, and clinical context is essential to avoid false-positive interpretation. 4

• The disease is likely underestimated in many countries, and initial seroma symptoms may be overlooked or misdiagnosed as benign complications. 6